启明医疗-B2023年度报告

2467455384118123125127128131245 Venus MedtechHangzhou Inc.12441,011,4433 123441,011,44345678910 2023 220VenusA550160004TAVRVenusA10VenusP-ValveVenusP-ValveVenusP-Valve50 Cardiovalve Target CE2070VenusP-Valve(FDA)IDEVenus-PowerXVenus-Vitae 2023 I. TAVRTAVR550 72.740%TPVRVenusP-Valve135TAVRVenusA10 VenusP-ValveFDAIDECenters for Medicare & Medicaid Service,CMSCMSCardiovalveVenus-VitaeVenus-PowerX TAVRVenusA-ValveVenusA-PlusVenusA-ProTPVRVenusP-ValveG SheathTAV0TAVRVenus-VitaeVenus-PowerXTMVRTTVRCardiovalveLiwen RF(RDN) VenusATAVR TAVRVenusA-ValveVenusA-PlusVenusA-ProVenusA-ValveNMPANMPATAVRVenusA-PlusNMPATAVR VenusA-ProVenusA-PlusVenusA-ProNMPATAVR VenusA21CIT2023VenusA-Valve80%VenusA-Valve9ChinaValveHangzhouVenusA-PlusVenusA-PlusVenusA-PlusTAVRVenusA VenusP-ValveTPVR (TPVR)VenusP-ValveCE MDR(RVOT)TPVRCE MDRIII VenusP-ValveNMPA≥3+TPVRVenusP-Valve50135VenusP-Valve VenusP-ValveVenusP-Valve CE100%0%96.87%95.38%(NYHA)Class III7.69%1.67%Class I27.69%90%VenusP-Valve3.64%54.5%0%36.4%2.22%VenusP-Valve VenusP-ValvePROTEUSFDAIDEJapan-US Harmonization By Doing60PROTEUSCenters for Medicare & Medicaid Service, CMSCMS Venus-VitaeTAVR TAVRVenus-VitaeSMART-ALIGN Venus-VitaeVenus-EnduraSeadaptVenus-VitaeVenus-VitaeVenus-Vitae Venus-Vitae Venus-PowerXTAVR TAVRVenus-PowerXPREVAILS Venus-PowerXVenus-Endura100%SeadaptVenus-PowerXVenus-PowerX Venus-PowerX CardiovalveTMVR/TTVR CardiovalveCardiovalve Cardiovalve55mm95% CardiovalveTARGET CECardiovalve Cardiovalve Liwen RF HOCMLiwen RF67986.1%68/7923.36 mm17.23 mm26.2%72.86 mmHg22.44 mmHg69.2% Liwen RFHOCM Liwen RF144Liwen RF88%Liwen RFNMPA Liwen RF RDN HealiumRenalyRDN RDN TAVRVenus-VitaeVenus-PowerXVenusP-ValveCardiovalve Cardiovalve 855429398263432314PCT25 3,500GMP20.64 ISO13485NMPAGMPFDAQSRMDRANVISARDCMDSAP ISO/IEC17025ISO13485MDRMDSAPBGMPCCNASMDSAP 22055052353,90085TAVRTAVRTPVR 50Shakeel Osman9CRTCSI PCR London Valve189 II. VenusA-ValveVenusA-ValveVenusP-ValveCE MDRNMPA 491.4406.520.9%VenusAVenusP-ValveVenusA83.4%88.1% 102.292.510.5%VenusAVenusP-Valve 314.023.9%389.277.2%79.2% 241.6148.063.2% 300.5260.415.4% 524.9527.50.5% 153.8192.220.0%Cardiovalve 314.0557.843.7% (HOCM)Liwen RF®HCMLiwen 4.93100% 310,863,000100%231,262,000111,000,000NMPA12163,038,000 Liwen RF®Liwen RF® Liwen RF®NMPALiwen RF®Liwen RF® 231.315.8 1617 2.222.0110.0% 62.744.640.6% 12.413.910.8% 6.334.381.6% 774.41,879.458.8% 705.9796.029 28.3%24.8% 802.91,976.959.4% 303.9(i)(ii)(iii)(iv) 569.1695.929 200,000,000Hangzhou Kuntai100,000,000 28. (i)HangzhouKuntai(ii) Hangzhou Kuntai100,000,0002,050,000 Hangzhou Kuntai100,000,0002,050,555.56 80,000,00080,000,000 (1) (2) (a)(i)(ii) (b)(c)(d)(e)3.10(1)3.10A3.213.27A (3) 13.24A 865 865735130 III. VenusP-Valve VenusP-ValveCardiovalveVenus-PowerXVenus-VitaeVenusP-ValveVenusP-Valve TAVRTAVR IV. (A)(i)(ii)(iii)(iv)(v)(vi)(B)(C)(D) • •••• • •••••• ••••••••TAVR ••••••• ••••••• •••• ••••• ••••••••• ••••• ••••• •••••• • • • 50 20Transcatheter Technologies GmbHEndoCor Pte. Ltd.Embryon, Inc. 39 48CEMDR 3910China eCapital Corporation2216 41 Kohlberg Kravis Roberts & Co. LP. 600867.SH600690.SHNYSE:CO221611463377 1146600867.SH (HKINED) 70 UFJ 140669661515261614771105870011288Sincere WatchHong Kong Limited444 Teesside Polytechnic 250,000 60 20 174810731204 49 600521600597 34 40 46201530.hk KEDGE I. TAVRTPVR IV. II. 13.51B(1) (i) (i)3.10(1)(ii)3.10A(iii)3.21(iv)3.27A (ii) (iii) (iv) (a)(b) 9.10. 9.7.(i)(ii) II. 3.13 486 39. (1) 221612524.75%(i)(ii) 14A.07 0.1%5%14A (2) (A)(B)(C)352,000,0002,981,47880,000,00014A(i)(ii)24.39. A.(i)250,000,000(ii)2,000,000(iii)100,000,000 B. (i)2,000,000(ii)500,000(iii)481,478 C. (i)50,000,000(ii)30,000,000 3%(i)(ii)–-24.(A)3%(B) (i)(ii)106,167,000 (i)80,000,000(ii) 24.39. XV(a)XV78(b)352(c) (1)H441,011,443441,010,235H1,208 XV23336336 (1)Horizon Binjiang LLC33,651,618HHorizon Binjiang LLC (2)32,644,302H12,094,675H1,208 •Adventure 03 Limited476,224HDinovaHealthcare Gamma Fund (USD) L.P.Adventure 03 LimitedDinova Venture PartnersGP III, L.P.Dinova Healthcare Gamma Fund (USD) L.P.Dinova Capital LimitedDinova Venture Partners GP III, L.P.Xin Nuo Tong Investment LimitedDinovaCapital LimitedXin Nuo Tong Investment LimitedAdventure 03 Limited •Dinova Venture Partners GP III, L.P.357,168HDinova Capital LimitedDinovaVenture Partners GP III, L.P.Xin Nuo Tong Investment LimitedDinova CapitalLimitedXin Nuo Tong Investment LimitedDinova Venture Partners GP III, L.P. •6,977,955H40% •DNA 01Hong Kong Limited2,056,615HDinovaHealthcare Delta Fund (USD) L.P.DNA 01Hong Kong LimitedDinova VenturePartners GP IV, L.P.Dinova Healthcare Delta Fund (USD) L.P.Dinova VentureCapital LimitedDinova Venture Partners GP IV, L.P.Xin Nuo Tong InvestmentLimitedDinova Venture Capital Limited 40%Xin Nuo TongInvestment LimitedDNA 01Hong Kong Limited •1,687,358H66.67%•539,355H•1,208Jupiter Holdings LimitedMercury HoldingLimit